Adicet Bio to Participate in Fireside Chat at JMP Securities Hematology Summit

Rhea-AI Summary

Adicet Bio (Nasdaq: ACET), a biotechnology firm specializing in allogeneic gamma delta T cell therapies, announced participation in a fireside chat at The JMP Securities Hematology Summit on December 15, 2020, at 2:00 PM ET. The discussion will be led by Chen Schor, CEO, and Stewart Abbot, Ph.D., COO. Investors can access a live audio webcast on the company’s website, followed by a 30-day archive. Adicet's innovative therapies aim to enhance tumor targeting and improve immune responses for cancer treatment.

News Market Reaction – ACET

+2.38%

+2.38% Session move

In the trading session that priced this news, ACET gained 2.38%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MENLO PARK, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Executive Officer and Stewart Abbot, Ph.D., Chief Scientific and Operating Officer, will participate in a fireside chat at The JMP Securities Hematology Summit on Tuesday, December 15, 2020 at 2:00 PM ET.

A live audio webcast of the fireside chat can be accessed on the Investors section of Adicet Bio’s website at https://investor.adicetbio.com. An archived replay will be available for 30 days following the presentation.

About Adicet Bio, Inc.
Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.

Adicet Bio., Inc.
Investor and Media Contacts
Anne Bowdidge
abowdidge@adicetbio.com

Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@sternir.com

FAQ

What is the date and time of the Adicet Bio fireside chat?

The Adicet Bio fireside chat is scheduled for December 15, 2020, at 2:00 PM ET.

Who will speak at the Adicet Bio fireside chat?

Chen Schor, President and CEO, and Stewart Abbot, Ph.D., Chief Scientific and Operating Officer, will participate.

How can I listen to the Adicet Bio fireside chat?

You can access the live audio webcast on Adicet Bio’s Investor section of their website.

Will there be a replay of the Adicet Bio fireside chat?

Yes, an archived replay will be available for 30 days following the presentation.

What type of therapies does Adicet Bio develop?

Adicet Bio develops allogeneic gamma delta T cell therapies aimed at treating cancer and other diseases.